Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study.
about
Brain-gut axis: from basic understanding to treatment of IBS and related disordersCharacterizing abdominal pain in IBS: guidance for study inclusion criteria, outcome measurement and clinical practice.Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.Recent advances in pharmacological treatment of irritable bowel syndrome.Glucagon-like peptides 1 and 2 and vasoactive intestinal peptide are neuroprotective on cultured and mast cell co-cultured rat myenteric neuronsEffect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome.Metabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome.On-demand treatment with alverine citrate/simeticone compared with standard treatments for irritable bowel syndrome: results of a randomised pragmatic studyTreatment of irritable bowel syndrome: beyond fiber and antispasmodic agents.Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.Pharmacological agents currently in clinical trials for disorders in neurogastroenterology.Existing and emerging therapies for irritable bowel syndrome.Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases.Systematic review: instruments to assess abdominal pain in irritable bowel syndrome.New and Investigational Agents for Irritable Bowel Syndrome.Novel investigational drugs for constipation-predominant irritable bowel syndrome: a review.GLP-1 based therapies: clinical implications for gastroenterologists.Inhibition of visceral nociceptors.New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond.Effects of GLP-1 and incretin-based therapies on gastrointestinal motor functionVisceral Inflammation and Immune Activation Stress the Brain.Glucagon-like peptide-1 analog, liraglutide, improves visceral sensation and gut permeability in rats.Role of Gut Microbiota-Gut Hormone Axis in the Pathophysiology of Functional Gastrointestinal Disorders.The Potential Role of the Dipeptidyl Peptidase-4-Like Activity From the Gut Microbiota on the Host Health
P2860
Q27024801-77475E02-7FDA-425B-8F35-31F3402F26F0Q30433548-53658BAD-8F09-4016-BE69-613BCA7FE525Q33958710-816038F8-0EEB-44B2-8F62-8F4120A90456Q33958853-3EA70613-8CCC-47D3-88CF-D10363EC3D56Q34215215-CC33019F-3E20-4BAC-BB89-D4B3A5B159ADQ34269632-8A2DD8D1-A6BB-47BF-BCF2-1FF3C5BF67E1Q34323319-108416AE-9196-4928-B6A6-A601EC42FC1DQ34804619-4B812A05-8825-4DF9-AFB5-1F4FD1EBAD95Q35018460-65B7B80A-02E6-4376-AD45-7453A0855704Q36302662-F1B30129-3E68-4EB7-89AC-7C17B2CEF117Q37200907-37CA35C8-12C9-4425-809A-482AD160C04AQ37857849-A020904E-A55F-4A2F-B3A2-E4D8C5EC17CAQ37954521-3676EF01-2E67-4C6D-A35E-878C31E4839AQ38029235-4BD48625-EC8C-4295-BC6C-053FF92A52D5Q38569948-D87379D2-9F39-4300-B78A-2E8050055033Q38601834-BBE03FC8-57AF-443E-8F4F-A51482D16402Q38696256-13690BF7-7073-4AE6-82AD-44D6E7D4FF0AQ38703292-51C76347-D232-4ABD-9793-61CAB86E1ABAQ38884350-BA7670E9-19E8-41CE-ACA1-8B7ADFD387A1Q42695148-74C5EFC1-9F54-4E27-B2BC-B2A05B070283Q42775479-525FF704-F477-49D8-BD3F-A6481C01B412Q47137050-052ED518-4D90-4839-97AA-A53ED7B57514Q50178398-2AC9BD2D-FFE5-4CCA-B158-480738269DA5Q55527145-F65F3C0B-51A4-45FC-A415-86EAC861F3A9Q58719667-AA9AEE27-FCC1-421B-BF6C-B07DB6B8A73F
P2860
Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Clinical trial: the glucagon-l ...... ontrolled, double-blind study.
@ast
Clinical trial: the glucagon-l ...... ontrolled, double-blind study.
@en
Clinical trial: the glucagon-l ...... ontrolled, double-blind study.
@nl
type
label
Clinical trial: the glucagon-l ...... ontrolled, double-blind study.
@ast
Clinical trial: the glucagon-l ...... ontrolled, double-blind study.
@en
Clinical trial: the glucagon-l ...... ontrolled, double-blind study.
@nl
prefLabel
Clinical trial: the glucagon-l ...... ontrolled, double-blind study.
@ast
Clinical trial: the glucagon-l ...... ontrolled, double-blind study.
@en
Clinical trial: the glucagon-l ...... ontrolled, double-blind study.
@nl
P2093
P1476
Clinical trial: the glucagon-l ...... ontrolled, double-blind study.
@en
P2093
E Björnssön
H Schambye
J Kristensen
P M Hellström
P304
P356
10.1111/J.1365-2036.2008.03870.X
P407
P577
2008-10-10T00:00:00Z